Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Apivita S A has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to MINA HAGHIGHATIAN, the 1 distinct examiner currently reviewing the company's filings. The prosecution is focused within 1 distinct art unit, reflecting a singular administrative path. MINA HAGHIGHATIAN is the busiest examiner with 1 busiest examiner pending office action, making her the primary point of contact for the company's current USPTO activity.
The concentration of the 1 pending office action under 1 distinct examiner means that the applicant only needs to manage one set of examiner preferences. Similarly, the 1 distinct art unit ensures that the technical review follows a single set of administrative procedures. The progress of the Biotechnology & Pharmaceuticals filing is entirely dependent on the schedule of MINA HAGHIGHATIAN. Practitioners should focus their efforts on the specific requirements of the busiest examiner, as there are no other examiners or art units to navigate. This lack of dispersion simplifies the management of the 1 pending office action within the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAGHIGHATIAN, MINA | 1 | 46.0% | +39.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18866328 | PRODUCTION METHOD OF A COMBINATORIAL DELIVERY SYSTEM OF VINE LEAVES AND PROPOLIS POLYPHENOLS FOR VARIOUS USES | HAGHIGHATIAN, MINA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18866328 | PRODUCTION METHOD OF A COMBINATORIAL DELIVERY SYSTEM OF VINE LEAVES AND PROPOLIS POLYPHENOLS FOR VARIOUS USES | HAGHIGHATIAN, MINA | — |
| Art Unit | Apps |
|---|---|
| 1616 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18866328 | PRODUCTION METHOD OF A COMBINATORIAL DELIVERY SYSTEM OF VINE LEAVES AND PROPOLIS POLYPHENOLS FOR VARIOUS USES | HAGHIGHATIAN, MINA | 1616 | §101§103§112 | Non-Final OA | — | Pending | Nov 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialApivita S A has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Mina Haghighatian has the most, with 1 of Apivita S A's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
